Tirzepatideyog ib qho tshiab dual qabzib-dependent insulinotropic polypeptide (GIP) thiab glucagon-zoo li peptide-1 (GLP-1) receptor agonist. Cov txheej txheem tseem ceeb ntawm nws qhov kev txiav txim yog nyob rau hauv ib txhij thiab proportionately activating ob lub plab hnyuv insulinotropic receptors. GIP thiab GLP-1 yog cov tshuaj insulinotropic hauv plab hnyuv uas tso tawm los ntawm cov hnyuv tom qab noj mov thiab tuaj yeem txhawb nqa cov tshuaj insulin los ntawm cov qog nqaij hlav pancreatic hauv cov piam thaj hauv cov ntshav, yog li txo cov ntshav qab zib kom zoo. Tsis tas li ntawd, Tirzepatide ua rau kom muaj kev txaus siab, ua rau lub plab zom mov qeeb, thiab inhibits qab los noj mov los ntawm kev ua kom cov receptors nyob rau hauv lub hypothalamus thiab lub paj hlwb, yog li txo qis calorie kom tsawg thiab ua tiav qhov hnyav poob. Piv nrog rau GLP-1 receptor agonists yooj yim, qhov tshwj xeeb ntawm Tirzepatide nyob rau hauv nws ib txhij ua kom GIP receptor signaling pathway. Kev sim thiab cov pov thawj kho mob qhia tau hais tias qhov no tsis yog tsuas yog tsim kom muaj kev sib koom ua ke ntawm kev txo cov ntshav qab zib thiab txo qhov hnyav, tab sis kuj tseem tuaj yeem txhim kho -cell muaj nuj nqi thiab muaj txiaj ntsig zoo rau cov roj metabolism hauv lub cev, thaum kawg ua rau muaj kev cuam tshuam cov metabolism hauv ntau theem.
|
|
|
|
|
|
|
|
Drug Foundation: Molecular Design of Dual Receptor Agonists
Tirzepatide yog lub ntiaj teb thawj dual receptor agonist rau qabzib -dependent insulinotropic polypeptide (GIP) thiab glucagon-zoo li peptide-1 (GLP-1). Nws cov qauv molecular yog linear polypeptide muaj li ntawm 39 amino acids. Los ntawm kev hloov kho tshuaj, nws ua tiav ntev - cov teebmeem ntev: ntawm txoj haujlwm 2 thiab 13, tsis yog -coding -amino isobutyric acid (Aib) residues tau qhia los txhim kho cov qauv kev ruaj ntseg thiab tiv thaiv kev degradation sai los ntawm intracellular peptidases; nyob rau ntawm K20 qhov chaw, ib qho hydrophilic linker khi rau C18 fatty acids, thiab nws txuas nrog albumin kom ncua lub neej ib nrab mus rau kwv yees li 5 hnub, txhawb nqa txoj kev tswj hwm subcutaneous ib zaug ib lim piam.
Qhov kev sib raug zoo ntawm cov tshuaj no rau GIP receptors yog qhov siab dua qhov ntawd rau GLP-1 receptors (kwv yees li 3 zaug). Cov yam ntxwv tshwj xeeb ntawm kev khi no ua rau nws nthuav tawm cov qauv tshwj xeeb hauv cov teeb liab hloov pauv: ua raws li cov tshuaj hormones ntuj tsim ntawm GIP receptors, thaum ntawm GLP-1 receptors, nws nyiam tsim cyclic adenosine monophosphate (cAMP) es tsis yog nrhiav cov protein-inhibitory. Qhov sib txawv ntawm cov teeb liab hloov pauv no ua rau nws ua rau muaj kev sib koom ua ke hauv kev txo cov piam thaj, poob phaus, thiab kev tswj hwm metabolic.
Core Mechanism: Synergistic Effects of Dual Signaling Pathways
Dual Insurance rau Glucose Regulation
Txhim kho cov tshuaj insulin
Tirzepatide activates PKA teeb liab txoj hauv kev los ntawm dual receptors, ua kom muaj txiaj ntsig zoo ntawm pancreatic hlwb rau cov piam thaj. Thaum cov ntshav qabzib nce siab, kev ua kom cov GIP receptor tuaj yeem txhawb nqa cov tshuaj insulin ntawm nws tus kheej, thaum ua kom cov GLP-1 receptor ntxiv ua kom cov nyhuv no. Cov kev sim tshuaj ntsuam xyuas tau pom tias nws cov nyhuv hypoglycemic yog qhov zoo dua rau cov receptor agonists ib leeg. Hauv kev sim 72 lub lis piam, qhov nruab nrab txo qis hauv glycated hemoglobin (HbA1c) hauv 15mg koob tshuaj yog 2.58%, deb tshaj qhov txo qis ntawm 1.44% ntawm degludec insulin.
Inhibition ntawm glucagon secretion
Kev ua haujlwm ntawm GLP-1 receptor ncaj qha inhibits qhov tso tawm ntawm glucagon los ntawm pancreatic hlwb, txo qis cov piam thaj hauv lub siab. GIP receptor plays lub luag haujlwm pabcuam hauv cov txheej txheem no, tsis ncaj qha inhibiting glucagon tso tawm los ntawm kev txhim kho cov teebmeem ntawm insulin. Qhov no ob txoj kev inhibition ua rau txo qis cov ntshav qabzib nrawm thaum zam kev pheej hmoo ntawm hypoglycemia uas tuaj yeem tshwm sim los ntawm ib leeg receptor agonists.
Ncua plab hnyuv
Kev ua kom lub GLP-1 receptor los ntawm cov hlab ntsha vagus signaling qeeb lub plab zom mov nrawm, ua kom lub sijhawm cov zaub mov nyob hauv plab, yog li ua kom cov ntshav qabzib hloov pauv tom qab noj mov. GIP receptor tuaj yeem txhim kho txoj kev zom zaub mov ntxiv los ntawm kev tswj cov kua qaub hauv plab thiab ua rau lub plab zom mov. Cov txheej txheem peripheral no txo cov ntshav qabzib siab tshaj plaws los ntawm kwv yees li 30% -40% hauv cov neeg mob.
Dual Tsav rau Kev Tswj Qhov hnyav
Txoj cai ntawm Lub Tsev Noj Qab Haus Huv
Tirzepatide activates GLP-1 receptor nyob rau hauv lub hypothalamus, ncaj qha inhibiting kev ua ntawm neurons nyob rau hauv lub qab los noj mov center thiab txo cov kev ntshaw rau cov khoom noj uas muaj calorie ntau ntau. Cov kev sim tsiaj tau pom tias nws tuaj yeem txo qhov noj cov zaub mov rog hauv cov nas los ntawm 40%, thaum tsis muaj qhov cuam tshuam loj rau kev noj zaub mov carbohydrate. Qhov kev xaiv qab los noj mov no yuav cuam tshuam nrog nws qhov kev nyiam rau GLP-1 receptor.
Reprogramming ntawm Fat Metabolism
Visceral fat breakdowns:Kev ua haujlwm ntawm GIP receptor txhawb nqa cov piam thaj thiab lipids los ntawm cov ntaub so ntswg adipose thaum pub mis, thiab txhim kho cov rog rog (lipolysis) thaum yoo mov. Cov kev sim tshuaj ntsuam xyuas tau pom tias nyob rau hauv pawg koob tshuaj 15mg, cov neeg mob 'visceral rog thaj tsam poob 34%, zoo dua li 22% ntawm semaglutide.
Dawb adipose nqaij browning:Tirzepatide tuaj yeem ua rau kev nthuav tawm ntawm cov protein tsis sib txuas 1 (UCP1) hauv cov ntaub so ntswg adipose dawb, txhawb nqa thermogenesis thiab nce kev siv zog. Cov txheej txheem no ua rau nws haus kwv yees li 100-150 kilocalories ib hnub twg txawm tias so.
Txhim kho lipid clearance:Los ntawm kev tswj hwm kev ua haujlwm ntawm lipoprotein lipase (LPL), nws ua kom nrawm nrawm ntawm triglycerides hauv cov ntshav thiab nce cov roj fatty acids. Hauv kev noj zaub mov -mob rog rog tus qauv, nws tuaj yeem txo qis triglyceride ntau ntau los ntawm 45% thiab txo cov nqaij rog lipid deposition los ntawm 60%.
Kev tswj hwm lub zog sib npaug
Tirzepatide activates thermogenic nyhuv ntawm cov nqaij ntshiv adipose (BAT), ua rau cov basal metabolic tus nqi kwv yees li 5% -10%. Cov nyhuv no tsis yog nyob ntawm kev tawm dag zog lossis tswj kev noj zaub mov thiab kav ntev li 24 teev. Tsis tas li ntawd, nws tuaj yeem txhim kho kev nkag siab ntawm insulin hauv cov leeg nqaij, ua kom cov piam thaj nce ntxiv thiab siv cov txiaj ntsig zoo.
Metabolic Network: Multi-system Coordinated Regulation
Optimization ntawm Lipid Metabolism
Tirzepatide txhim kho lipid profile tau zoo: nws txo qis triglyceride (TG) qib los ntawm kwv yees li 40%, nce siab -cov roj lipoprotein ntom ntom (HDL-C) li ntawm 15%, thiab txo qis oxidative hloov pauv ntawm qis- ntom lipoprotein cholesterol. (LDL-C). Qhov kev txhim kho no yog ib feem los ntawm nws lub peev xwm los txhim kho adiponectin qib - ntawm koob tshuaj 10mg, qib adiponectin nce 26% hauv 26 lub lis piam, yog li txhim kho insulin rhiab heev thiab inhibiting inflammatory teb.
Kev tiv thaiv kab mob siab
Hauv cov txheej txheem metabolic tsis ua haujlwm-mob ntsig txog kab mob siab (MASLD), Tirzepatide txo qis daim siab lipid uptake thiab deposition los ntawm down- tswj kev qhia ntawm fatty acid translocase (CD36) thiab tsw-binding protein (OBP2A). Tsis tas li ntawd, nws tuaj yeem cuam tshuam txoj hauv kev mitochondrial oxidative phosphorylation, txo oxidative kev nyuaj siab thiab lipid peroxidation, thiab ncua kev loj hlob ntawm tus kab mob. Kev sim tshuaj ntsuam xyuas tau pom tias nws tuaj yeem txo cov rog hauv siab los ntawm 63% thiab txo lub siab tawv los ntawm 28%.
Kev txo qis hauv plawv plawv
Tirzepatide tiv thaiv kab mob plawv los ntawm ntau lub tshuab:
Txo cov ntshav siab: Cov ntshav siab systolic txo qis los ntawm qhov nruab nrab ntawm 5-7 mmHg, thiab cov ntshav siab diastolic poob los ntawm 3-4 mmHg.
Txhim kho arteriosclerosis: Los ntawm kev txo qis vascular endothelial o thiab oxidative stress, pulse wave velocity (PWV) raug txo los ntawm kwv yees li 10%.
Anti-cov nyhuv inflammatory: inhibiting kev qhia ntawm pro-inflammatory cytokines (xws li TNF- , IL-6), thiab txo qhov tsim ntawm atherosclerotic plaques.
Hauv txoj kev tshawb fawb SUMMIT, nws tuaj yeem txo qhov kev pheej hmoo ntawm cov hlab plawv tuag lossis kev puas tsuaj ntawm lub plawv tsis ua haujlwm hauv cov neeg mob rog rog nrog kev khaws cia ejection feem (HFpEF) los ntawm 38%.
Cov txiaj ntsig kho mob: Mechanism- tau tsav cov kev kho mob zoo
Qhov tseem ceeb poob ceeb thawj
SURMOUNT-1 kev sim pom tau tias pawg koob tshuaj 15mg tau ua tiav qhov hnyav nruab nrab ntawm 20.9% (kwv yees li 23 kg) hauv 72 lub lis piam, thiab 36% ntawm cov neeg mob tau poob phaus ntau dua lossis sib npaug li 25%, uas tau dhau los ntawm qhov kev txiav txim siab poob phaus (xws li 20% ntawm kev phais mob gasket). Qhov kev cuam tshuam no yog vim nws txoj haujlwm ntau lub hom phiaj:
Kev tsis qab los noj mov: Txo tus neeg mob cov calories txhua hnub los ntawm kwv yees li 500-700 kilocalories.
Kev siv hluav taws xob ntau ntxiv: Tus nqi basal metabolic nce li ntawm 10%, thiab kev tawm dag zog ua kom zoo dua los ntawm 15%.
Kev nrawm nrawm nrawm: Cov roj tawg ntawm cov visceral nce 3 zaug, thiab qhov tawg ntawm cov rog subcutaneous nce 2 zaug.
Kev txhim kho ntawm metabolic syndrome
Tirzepatide tuaj yeem txhim kho cov ntsiab lus ntawm metabolic syndrome:
Kev tswj ntshav qabzib: Tus nqi ntawm cov ntshav qab zib tso tawm (HbA1c <6.5% thiab tsis xav tau tshuaj) mus txog 52%.
Kev tswj ntshav siab: Tus nqi ntawm cov ntshav siab nce mus txog tus qauv (< 130/80 mmHg) nce 25%.
Lipid optimization: Tus nqi ntawm lipid txawv txav rov qab (TG < 1.7 mmol / L thiab HDL -C > 1.0 mmol / L) nce 40%.
Kev nyab xeeb thiab kam rau ua
Txawm hais tias Tirzepatide tuaj yeem ua rau lub plab zom mov (xws li xeev siab thiab raws plab, nrog rau qhov tshwm sim ntawm kwv yees li 40%-60%), lawv feem ntau mob me me mus rau nruab nrab thiab maj mam txo qis thaum lub sijhawm noj tshuaj nce ntxiv. Qhov tshwm sim ntawm cov xwm txheej tsis zoo (xws li mob pancreatitis, hypoglycemia) tsawg dua 0.5%, thiab tsis muaj qhov sib txawv tseem ceeb piv rau pawg placebo. Cov ntaub ntawv ntev -cov ntaub ntawv kev nyab xeeb (xws li 5-xyoo kev soj ntsuam) qhia tias tsis muaj qhov txawv txav hauv lub siab thiab lub raum ua haujlwm, cov thyroid ua haujlwm, thiab cov cim qog.
Yav tom ntej Prospects: Mechanism Exploration and Clinical Application
Lub dual receptor agonistic mechanism ntawm tirzepatide muaj ib tug tshiab paradigm rau kev kho mob ntawm metabolic kab mob. Kev tshawb fawb tam sim no yog tsom rau:
Mechanism deepening
Tshawb nrhiav tus ntoo khaub lig- kev tswj hwm kev sib txuas ntawm GIP/GLP-1 txoj hauv kev, thiab qhia nws cov kev cuam tshuam hauv nruab nrab ntawm lub paj hlwb, cov ntaub so ntswg adipose, thiab daim siab.
Indications expansion
Ntsuam xyuas nws cov peev xwm ua tau zoo nyob rau hauv tsis yog - kab mob cawv fatty siab (NASH), obstructive pw tsaug zog apnea (OSA), thiab Alzheimer's kab mob, thiab lwm yam.
Kev sib xyaw ua ke
Kawm txog nws cov teebmeem kev sib koom ua ke nrog SGLT-2 inhibitors, insulin, lossis tshuaj tiv thaiv kev rog kom ua kom zoo dua rau kev kho mob.
Raws li cov tshuaj tseem ceeb hauv thaj chaw ntawm cov tshuaj metabolic, Tirzepatide, los ntawm nws qhov tshwj xeeb dual -kev ua haujlwm mechanism, redefines cov qauv kev kho mob rau ntshav qab zib thiab rog. Nrog rau hauv - tsom xam qhov tob ntawm nws cov txheej txheem molecular, cov tshuaj no xav tias yuav coj cov kev kho mob zoo dua thiab muaj txiaj ntsig zoo rau ntau pua lab tus neeg mob uas muaj kab mob metabolic thoob ntiaj teb.